*March 2023* Results: Fifty patients were allocated to the control group, and 46 were allocated to the experimental group (NTG); among these, 26 (52%) had EGFRm in the control group and 21 (45.7%) had EGFRm in the NTG arm. In terms of the iORR, patients in the NTG group had a…

*March 2023* The antibody-drug conjugate (ADC) patritumab deruxtecan (HER3-DXd) elicited responses in previously treated patients with EGFR-mutated metastatic or unresectable non–small cell lung cancer (NSCLC), according to updated data from a phase 1 trial (NCT03260491). Findings from a phase 1/2 trial (NCT02980341) also showed that the agent induced a response in…

*March 2023* NOTE:  DURING TTLC 23, DRS. BALAZS HALMOS AND MARK SOCINSKI PRESENTED THE EVIDENCE FOR AND AGAINST CONTINUED TYROSINE KINASE INHIBITORS USE WITH CHEMOTHERAPY FOR EGFR-POSITIVE PATIENTS WITH DISEASE PROGRESSION. EGFR tyrosine kinase inhibitors (TKIs) have been integrated into early treatment for non-small cell lung cancer (NSCLC) patients with…

*February 2023* Osimertinib, an epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), potently and selectively inhibits EGFR-TKI-sensitizing and EGFR T790M resistance mutations. In the Phase III FLAURA study (NCT02296125), first-line osimertinib improved outcomes vs comparator EGFR-TKIs in EGFRm advanced non-small cell lung cancer. This analysis identifies acquired resistance mechanisms to…

*March 2023* The antibody-drug conjugate (ADC) fam-trastuzumab deruxtecan-nxki (Enhertu) met the prespecified target for objective response rate (ORR) and demonstrated durable responses in heavily pretreated patients with HER2-expressing advanced solid tumors in the phase 2 DESTINY-PanTumor02 trial (NCT04482309).1 The trial included previously treated patients with locally advanced, unresectable, or metastatic…

*April 2023* There is still a lot to be learned regarding resistance mechanisms in EGFR-mutant NSCLC, especially when osimertinib is used in the first-line setting and especially in the category of pathway indifference resistance cancers. In this issue of the Journal of Thoracic Oncology, Choudhury et al.10 set out to characterize mechanisms of…

*February 2023* RAHWAY, N.J.--(BUSINESS WIRE)-- Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today provided updates on two Phase 3 trials, KEYNOTE-641 and KEYNOTE-789. Merck also announced that the Phase 3 KEYNOTE-789 trial evaluating KEYTRUDA in combination with pemetrexed plus platinum-based chemotherapy did not meet its…

*January 2023* Introduction Epidermal growth factor receptor (EGFR) mutations drive a subset of non-small cell lung cancer (NSCLC). Patients harboring the common EGFR mutations, deletion of exon 19 (Ex19del) and L858R, respond well to osimertinib, a third-generation tyrosine kinase inhibitor. However, the effect of osimertinib on NSCLC with atypical EGFR…

*November 2022* The uncommon EGFR mutations remain a perennial challenge to treat. They constitute a heterogenous group of molecular alterations within exons 18 to 21, which include substitution mutations of G719X, L861Q, and S768I, and exon 20 insertions, with prevalence of approximately 10% to 20% of EGFR mutation-positive NSCLC. EGFR mutations…

*January 2023* In an interview with OncLive®, Spira highlighted the top advancements across NSCLC in 2022, emphasized the need for increased genetic testing to inform treatment decisions, and previewed other agents under development. Spira is the co-director of the Virginia Cancer Specialists Research Institute and the Phase I Trial Program, the…